Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid

US11141489B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Dieter Kadereit · Kelkheim, DE
• Michael Wagner · Frankfurt am Main, DE
• Thomas Olpp · Frankfurt am Main, DE
• Nino Meyer · Frankfurt am Main, DE
• Martin Bossart · Frankfurt am Main, DE
• Andreas Evers · Frankfurt am Main, DE
• Peyman Sakhaii · Frankfurt am Main, DE
• Pradeep K. Dhal · Westford, US
• Paul A. Konowicz · Farnham, GB
• James Stefano · Bound Brook, US
• Nils Poth · Frankfurt am Main, DE

Key dates

• Filing date: Oct 28, 2019
• Grant date: Oct 12, 2021
• Expiry date: Oct 28, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K14/605
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L1-L2-L-L-Y—R20 groups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising the conjugate or the pharmaceutically acceptable salt thereof as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon receptor agonist.